IDiyas

For the Inventor, By the Inventor

Charlestown, RI, United States of America

Geraldine C B Harriman

USPTO Granted Patents = 21


Average Co-Inventor Count = 4.6

ph-index = 6

Forward Citations = 100(Granted Patents)


Location History:

  • Charlestown, RI (US) (2003 - 2015)
  • Brookline, MA (US) (2007 - 2017)

Company Filing History:

goldMedal19 out of 850 
 
Millennium Pharmaceuticals Limited
 patents
silverMedal3 out of 272 
 
Kyowa Hakko Kirin Co., Limited
 patents
bronzeMedal2 out of 730 
 
Kyowa Hakko Kogyo Co., Ltd.
 patents
4. 2 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2003-2017

Loading Chart...
Loading Chart...
21 patents (USPTO):
1. 9663537 - Chemokine receptor antagonists and methods of use (2017-05-30),
2. 9334283 - CCR1 antagonists and methods of use thereof (2016-05-10),
3. 9035096 - CCR9 inhibitors and methods of use thereof (2015-05-19),
4. 8653096 - Chemokine receptor antagonists and methods of use thereof (2014-02-18),
5. 8569543 - CCR9 inhibitors and methods of use thereof (2013-10-29),
6. 8394817 - CCR1 antagonists and methods of use therefor (2013-03-12),
7. 8058287 - Chemokine receptor antagonists and methods of use therefor (2011-11-15),
8. 8030517 - CCR9 inhibitors and methods of use thereof (2011-10-04),
9. 7999109 - CCR9 inhibitors and methods of use thereof (2011-08-16),
10. 7977350 - CCR1 antagonists and methods of use therefor (2011-07-12),
11. 7951801 - Beta-carbolines useful for treating inflammatory disease (2011-05-31),
12. 7820717 - CCR9 inhibitors and methods of use thereof (2010-10-26),
13. 7732459 - CCR1 antagonists and methods of use therefor (2010-06-08),
14. 7659272 - CCR9 inhibitors and methods of use thereof (2010-02-09),
15. 7541365 - Chemokine receptor antagonists and methods of use therefor (2009-06-02),

Title: Geraldine C B Harriman: Innovator in Chemokine Research

Introduction

Geraldine C B Harriman, based in Charlestown, Rhode Island, is a notable inventor with an impressive portfolio of 21 patents. Her innovative contributions primarily focus on chemokine receptor antagonists, which have significant implications in treating diseases associated with leukocyte recruitment and activation.

Latest Patents

One of Harriman's latest patents involves the development of novel compounds and methods for treating diseases related to aberrant leukocyte recruitment. This patent outlines a method that includes administering an effective amount of the compound, along with its physiologically acceptable salts. Another significant patent focuses on CCR1 antagonists, providing compounds with specific formulas, particularly involving halogen groups. This invention also includes various compositions and treatment methods that utilize these compounds to address various diseases or disorders through the potential antagonist activity of CCR1.

Career Highlights

Geraldine Harriman has built an extensive career, contributing to advancements in pharmacology and biochemical research. She has been associated with prestigious companies, including Millennium Pharmaceuticals Limited and Kyowa Hakko Kirin Co., Limited. Her work in these organizations has positioned her as an influential figure in the biotech industry.

Collaborations

Throughout her career, Harriman has collaborated with reputable colleagues such as Kenneth Gordon Carson and Paul E Fleming. These partnerships have enriched her research endeavors, allowing for innovative approaches to biochemical challenges and the development of novel therapeutic solutions.

Conclusion

Geraldine C B Harriman exemplifies a dedicated innovator in chemokine research with a substantial impact on the field through her patents. Her work reflects a commitment to advancing medical science and enhancing treatment methodologies, solidifying her legacy as a leading inventor in her area of expertise.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…